Your browser is no longer supported. Please, upgrade your browser.
Settings
XENE [NASD]
Xenon Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-1.01 Insider Own1.60% Shs Outstand36.83M Perf Week-3.50%
Market Cap774.23M Forward P/E- EPS next Y-2.26 Insider Trans-2.49% Shs Float23.58M Perf Month10.05%
Income-36.10M PEG- EPS next Q-0.48 Inst Own83.30% Short Float2.79% Perf Quarter-8.60%
Sales29.40M P/S26.33 EPS this Y47.40% Inst Trans18.47% Short Ratio4.43 Perf Half Y55.07%
Book/sh7.29 P/B2.54 EPS next Y-46.80% ROA-16.20% Target Price26.88 Perf Year54.04%
Cash/sh6.56 P/C2.82 EPS next 5Y- ROE-18.30% 52W Range9.32 - 21.94 Perf YTD20.29%
Dividend- P/FCF- EPS past 5Y6.00% ROI-19.60% 52W High-15.68% Beta1.42
Dividend %- Quick Ratio24.60 Sales past 5Y15.60% Gross Margin- 52W Low98.50% ATR0.93
Employees122 Current Ratio24.60 Sales Q/Q-38.00% Oper. Margin- RSI (14)48.62 Volatility4.26% 5.30%
OptionableYes Debt/Eq0.00 EPS Q/Q-90.40% Profit Margin- Rel Volume0.50 Prev Close18.60
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume148.50K Price18.50
Recom1.30 SMA20-0.57% SMA500.09% SMA20023.75% Volume75,528 Change-0.54%
Oct-02-20Initiated SVB Leerink Outperform $22
Jul-21-20Initiated Needham Buy $22
Jun-01-20Resumed Jefferies Buy $23
Mar-25-20Initiated Wedbush Outperform $23
Jan-08-20Initiated William Blair Outperform
Sep-20-19Initiated Guggenheim Buy $25
Aug-08-18Reiterated Stifel Buy $9 → $15
Mar-13-17Initiated Jefferies Buy $13
Oct-21-16Initiated Stifel Buy $18
Sep-26-16Initiated Guggenheim Buy $20
Apr-14-16Reiterated Jefferies Buy $10 → $13
Oct-30-15Resumed Jefferies Buy
Dec-02-14Initiated Canaccord Genuity Buy $15
Jun-03-21 05:45PM  
May-31-21 04:01PM  
May-17-21 04:05PM  
May-11-21 04:01PM  
02:30PM  
May-04-21 04:05PM  
Apr-13-21 09:28AM  
Apr-08-21 04:03PM  
Mar-29-21 04:05PM  
Mar-12-21 12:19PM  
Mar-10-21 12:49AM  
Mar-09-21 04:05PM  
Mar-08-21 04:05PM  
Mar-01-21 06:25PM  
05:25PM  
04:01PM  
02:30PM  
Feb-23-21 08:45AM  
Feb-22-21 04:01PM  
Feb-12-21 08:18AM  
Feb-03-21 04:25PM  
Jan-14-21 08:00AM  
Dec-07-20 04:03PM  
Nov-13-20 09:00AM  
Nov-09-20 02:15PM  
Nov-07-20 12:31AM  
Nov-06-20 01:35PM  
Nov-05-20 06:45PM  
04:01PM  
02:45PM  
Nov-02-20 05:26PM  
Oct-08-20 08:02AM  
08:00AM  
Sep-28-20 08:02PM  
Sep-22-20 03:41PM  
Aug-17-20 08:30AM  
Aug-06-20 08:20PM  
04:01PM  
Aug-04-20 04:01PM  
Jul-30-20 04:01PM  
Jul-12-20 01:31PM  
Jun-17-20 04:04PM  
Jun-08-20 02:06AM  
Jun-01-20 04:20PM  
11:31AM  
May-25-20 08:28AM  
May-22-20 10:23AM  
04:30AM  
May-21-20 05:15PM  
04:01PM  
02:30PM  
May-14-20 04:01PM  
Mar-31-20 08:30AM  
Mar-28-20 12:12AM  
Mar-26-20 04:01PM  
Mar-23-20 09:06AM  
Mar-09-20 04:01PM  
02:30PM  
Mar-02-20 04:01PM  
Feb-14-20 11:11AM  
Feb-06-20 11:53AM  
Feb-04-20 11:44AM  
08:13AM  
Feb-03-20 11:11AM  
Jan-27-20 04:01PM  
Jan-24-20 10:26AM  
Jan-23-20 12:00PM  
07:24AM  
Jan-22-20 08:49PM  
04:01PM  
Jan-13-20 08:30AM  
Jan-10-20 08:08AM  
Dec-11-19 11:23AM  
Dec-07-19 08:45AM  
Dec-06-19 08:45AM  
Dec-03-19 05:23PM  
07:59AM  
Dec-02-19 07:45AM  
07:30AM  
Nov-21-19 09:44AM  
Nov-15-19 08:45AM  
Nov-11-19 09:45AM  
Nov-05-19 04:01PM  
Oct-29-19 04:30PM  
Oct-25-19 02:20PM  
Oct-16-19 08:30AM  
Oct-01-19 07:21AM  
Sep-25-19 04:05PM  
11:49AM  
Sep-24-19 09:36AM  
Sep-17-19 04:05PM  
Sep-09-19 04:01PM  
Sep-05-19 11:22AM  
Aug-14-19 12:51PM  
Aug-06-19 09:33PM  
Jul-31-19 04:01PM  
Jul-09-19 11:11AM  
Jun-14-19 06:55PM  
Jun-05-19 08:10AM  
Jun-03-19 05:58PM  
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in Phase II clinical trials. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy; and with Flexion Therapeutics, Inc. to develop FX301 (XEN402, a Nav1.7 inhibitor) for the treatment of post-operative pain. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBIN SHERRINGTONEVP, Strategy & InnovationMay 28Option Exercise3.8125,71997,90740,491Jun 01 04:11 PM
ROBIN SHERRINGTONEVP, Strategy & InnovationMay 28Sale18.816,067114,12032,232Jun 01 04:11 PM
HOLLER FRANK ADirectorMay 27Option Exercise3.7639,094146,993160,628Jun 01 04:07 PM
HOLLER FRANK ADirectorMay 27Sale18.6811,064206,701143,653Jun 01 04:07 PM
PIMSTONE SIMON N.CEOMay 24Option Exercise3.7622,63385,100232,819May 26 04:11 PM
TARNOW MICHAEL MDirectorMay 18Option Exercise3.728,22930,61277,942May 20 04:18 PM
Hayden Michael RDirectorMay 18Option Exercise3.853,50013,475116,206May 20 04:13 PM
Hayden Michael RDirectorFeb 18Option Exercise2.9341,152120,47292,076Feb 18 05:59 PM
Hayden Michael RDirectorFeb 16Option Exercise2.685,14413,786112,706Feb 18 05:59 PM
AZAB MOHAMMADDirectorDec 15Option Exercise3.763,08611,60363,733Dec 15 04:39 PM
TARNOW MICHAEL MDirectorOct 28Option Exercise3.7610,28838,68380,001Oct 29 04:27 PM
PATOU GARYDirectorOct 28Option Exercise3.762,0577,73423,573Oct 29 04:20 PM